Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis

Clinical Rheumatology

Volumn 33, Issue 4, 2014, Pages 531-536

  Danieli, Maria Giovanna ^a,b   Moretti, Romina ^a   Gambini, Simona ^a   Paolini, Luca ^a   Gabrielli, Armando ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Polo Didattico Scientifico   (Italy)

Author keywords

Autoimmune disease; Dermatomyositis; Immune mediated disease; Inflammatory myopathies; Intravenous immunoglobulin; Polymyositis; Subcutaneous immunoglobulin

Indexed keywords

CREATINE KINASE; CYCLOSPORIN A; HUMAN IMMUNOGLOBULIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFUSION PUMP; MEDICAL RESEARCH COUNCIL SCORE; MUSCLE STRENGTH; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POLYMYOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REMISSION; SCORING SYSTEM; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; COHORT ANALYSIS; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INFUSIONS, SUBCUTANEOUS; MIDDLE AGED; PATIENT SATISFACTION; POLYMYOSITIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898848245     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2478-x     Document Type: Article

References (15)

1. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292(344-7):403-407
2. Dalakas MC (2012) Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 11(3):203-206
3. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10(3):144-149
4. Berger M (2011) L-proline-stabilized human IgG: Privigen® 10 % for intravenous use and Hizentra® 20 % for subcutaneous use. Immunotherapy 3(2):163-176
5. Troyanov Y, Targoff IN, Trembaly JL et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84:231-249
6. Borte M, Pac M, Serban M et al (2011) Efficacy and safety of Hizentra®, a new 20 % immunoglobulin preparation for subcutaneous administration, in paediatric patients with primary immunodeficiency. J Clin Immunol 31(5):752-761
7. Fernandez-Cruz E, Kaveri SV, Peter H-H et al (2009) Intravenous immunoglobulin in immunodeficiencies and autoimmunity. Clin Exp Immunol 158(Suppl1):60-67
8. Misbah SA, Baumann A, Fazio R et al (2011) A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 16(2):92-97
9. Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993-2000
10. Kivity S, Katz U, Daniel N et al (2010) Evidence for the use of intravenous immunoglobulins - a review of the literature. Clin Rev Allergy Immunol 38(2-3):201-269
11. Vaitla PM, McDermott EM (2010) The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology 49(6):1040-1048
12. Seite JF, Shoenfeld Y, Youinou P, Hillion S (2008) What is the content of the magic draft IVIg? Autoimmun Rev 7(6):435-439
13. Kessel A, Ammuri H, Peri R et al (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179(8):5571-5575
14. Jolles S, Bernatowska E, de Gracia J et al (2011) Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 141(1):90-102
15. Martin A, Lavoie L, Goetghebeur M, Schellenberg R (2013) Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med 23(1):55-60